Drilldown: Medicines

None (1) · 2-FDCK (1) · 3-HO-PCE (1) · 3-HO-PCP (1) · 3-MeO-PCE (1) · 3-MeO-PCP (1) · 4-MeO-PCP (1) · Asenapine (1) · Celecoxib (1) · Chlorpromazine (1) · Deschloroketamine (1) · Dextromethorphan (1) · Dextrorphan (1) · Diphenidine (1) · Droperidol (1) · Ephenidine (1) · Eticyclidine (1) · Fluphenazine (1) · Ibogaine (1) · Ibuprofen (1) · Iloperidone (1) · Indomethacin (1) · Loxapine (1) · Lurasidone (1) · Meloxicam (1) · Methoxetamine (1) · Molindone (1) · Nitrous oxide (1) · O-PCE (1) · Paliperidone (1) · Perphenazine (1) · Pimozide (1) · Salvia divinorum (1) · Salvinorin A (1) · Thioridazine (1) · Thiothixene (1) · Trifluoperazine (1) · Xenon (1) · Ziprasidone (1)

None (17) · Advil, Motrin, IBU, Caldolor (IV), NeoProfen (neonatal IV) (1) · Celebrex (oral capsules), Elyxyb (oral solution, for acute migraine) (1) · DXM (1) · DXO (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Indocin (oral, IV, suppository), Tivorbex (low-dose), Indo-Lemmon (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Mobic, Vivlodex (lower-dose capsules), Anjeso (IV) (1) · Navane (1) · Orap (1) · Prolixin (1) · Saphris (1) · Spravato (1) · Stelazine (1) · Thorazine (1) · Trilafon (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (4) · Active metabolite of DXM; NMDA antagonist (1) · Butyrophenone D2 antagonist (1) · Contains salvinorin A (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Phenothiazine D2 antagonist (4) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00000019-QINU`"' Once-daily dosing is a clinical advantage over short-half-life NSAIDs'"`UNIQ--ref-0000001A-QINU`"'. (1)

None (34) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (2) · '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (1)

None (34) · 200-400 mg PO every 4-6 hours as needed. OTC max 1200 mg/day without provider direction; prescription max 3200 mg/day divided (1) · 7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg (1) · Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours (1)

None (34) · 28 mg/device (each dose uses 2 devices) (1) · Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) (1) · Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL (1) · Tablets 200, 400, 600, 800 mg; capsules 200 mg; oral suspension 100 mg/5 mL; chewable tablets 100 mg; injection 100 mg/mL (Caldolor) (1) · Tablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso) (1)

None (34) · 15 mg/day (oral); 30 mg IV once daily (Anjeso) (1) · 200 mg/day (typical adult oral) (1) · 3200 mg/day (Rx); 1200 mg/day (OTC, without provider direction) (1) · 400 mg/day for chronic indications; higher for short-term acute pain (1) · 84 mg per session (1)

None (34) · Intranasal (under direct medical supervision) (1) · intravenous (1) · intravenous (Caldolor (1) · intravenous (PDA closure only) (1) · NeoProfen) (1) · Oral (4) · rectal (1)

None (34) · 30-60 minutes (1) · 30-60 minutes (oral) (1) · 30-60 minutes (oral); rapid relief in acute gout (1) · Analgesic effect within hours; full anti-inflammatory effect over 1-2 weeks (1) · Within hours of first administration (1)

None (34) · 12-24 hours (1) · 24 hours (once-daily dosing supported by long half-life) (1) · 4-6 hours (1) · 4-6 hours (IR); 24 hours (ER) (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (34) · 15-20 hours'"`UNIQ--ref-00000020-QINU`"' (1) · 2-4 hours'"`UNIQ--ref-00000026-QINU`"' (1) · 4-5 hours'"`UNIQ--ref-00000026-QINU`"' (1) · ~11 hours'"`UNIQ--ref-00000029-QINU`"' (1) · ~7-12 hours (1)

None (34) · ~100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~48% intranasal (1) · ~80-100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~89% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~99% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1)

None (34) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000022-QINU`"' (1) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000028-QINU`"' (1) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' (1) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' (1) · Avoid; may cause fetal harm (1)

None (34) · Rx, Schedule III (US). REMS program required. (1) · [[USLegal:Over-the-counter|OTC]] in the US at ≤200 mg per tablet / ≤1200 mg/day; [[USLegal:Prescription only|Rx-only]] at higher strengths and indications (1) · [[USLegal:Prescription only|Rx-only]] in US (3)